アルツハイマー病の初期アミロイド病変と認知障害を誘発するサブキュラーパルバルブミン内ニューロンの過活性

Yan-Bing Chen^1,2, Bo Jiang³, Kai Zhuang¹

¹Department of Neurology, Zhongshan Hospital of Xiamen University, and Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, Fujian, 361102, China.

Molecular psychiatry

|September 5, 2025

まとめ

初期のアルツハイマー病 (AD) は,下皮の縮を伴う. サビキュラムの過剰活性パルバルブミン内ニューロンを抑制すると,アミロイドβの蓄積が減り,ADのマウスモデルでの認知機能が改善されます.

科学分野:

神経科学
細胞生物学
病理学について

背景:

サビキュラム縮は認知機能低下に関連した早期アルツハイマー病 (AD) マーカーです.
アルツハイマー病の初期に潜眼の脆弱性を引き起こすメカニズムはまだ十分に理解されていません

研究の目的:

初期のAD病理の基礎となる細胞メカニズムを研究する.
早期のAD介入のための潜在的な治療標的を特定する.

主な方法:

ADの5×FADマウスモデルを使用した.
レーザーマイクロ解剖,プロテオミック分析,単核RNA配列決定 (snRNA-seq) を採用した.
標的ニューロン阻害のための化学遺伝的アプローチを適用した.

主要な成果:

初期のアミロイドベータ (Aβ) 蓄積とサビキュラムにおけるGABAergicニューロン不調を特定した.
発見されたパルバルブミン内ニューロン (PV-INs) は,多動性によってAβ病理を駆動する.
PV-IN過活性を抑制するとAβが減少し,認知機能が改善され,ADマウスのタンパク質ホメオスタシスが回復することが示された.
ヒトのAD患者における高PV発現が確認された.

結論:

サビキュラルのパルバルブミン内ニューロンは,初期のAD病理学的要因の1つです.
PV-INの過剰活性化をターゲットにすることで,ADの早期介入に有望な治療戦略を提供できます.
タンパク質のホメオスタシスとリソソーム機能の回復は,PV-INの抑制の結果である.

さらに関連する動画

08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

42.9K

08:16

Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus

Published on: June 17, 2015

18.4K

関連する概念動画

01:26

Alzheimer's Disease: Overview

666

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

666

01:22

Alzheimer's Disease: Treatment

260

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

260

01:15

Functional Brain Systems: Limbic System

3.8K

The limbic system, often called the "emotional brain," is a complex set of structures located deep within the brain. The intricate network of the limbic system supports a wide range of psychological functions, from emotional regulation to memory formation and sensory processing. This functional brain region encompasses specific parts of the diencephalon and the cerebrum, integrating the higher mental functions of the cerebral cortex with the primitive emotional responses of the deep brain...

3.8K

03:03

Amyloid Fibrils

9.8K

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...